← ANALYST RATINGS · TIPRANKS
Neurocrine (NBIX): analyst forecast and price target
Price targets and ratings of
Analyst consensus
Strong Buy18 Buy3 Hold0 Sell
Ratings of 21 analysts in the last 3 months · top analysts only12-month forecast
$206+52.2% upside
Based on 21 price targets given in the last 3 months, the average target is $206, the highest $253, the lowest $150. The average is +52.2% from the last price of $136.
Highest target $253
Average target $206
Lowest target $150
Analyst ratings 37
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $158 → $160+1.3% | Buy | +17.9% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $160 → $162+1.2% | Buy | +19.4% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $156 → $158+1.3% | Buy | +16.4% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $151 → $153+1.3% | Buy | +12.7% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $157 → $159+1.3% | Buy | +17.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $158 → $160+1.3% | Buy | +17.9% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $204 | Buy | +50.3% | Reiterated | 16.10.26on TipRanks 07:35 | +0.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $167 → $158−5.4% | Buy | +16.4% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $169 → $160−5.3% | Buy | +17.9% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $165 → $156−5.5% | Buy | +15.0% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $160 → $151−5.6% | Buy | +11.3% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $165 → $157−4.8% | Buy | +15.7% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $180 → $158−12.2% | Buy | +16.4% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $187 | Buy | +37.8% | Reiterated | 13.10.26on TipRanks 07:09 | −4.4%next day +1.7% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $200 | Buy | +47.4% | Reiterated | 13.10.26on TipRanks 06:55 | −4.4%next day +1.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $165 → $167+1.2% | Buy | +23.1% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $167 → $169+1.2% | Buy | +24.5% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $163 → $165+1.2% | Buy | +21.6% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $158 → $160+1.3% | Buy | +17.9% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $164 → $165+0.6% | Buy | +21.6% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $164 → $150−8.5% | Hold | +10.5% | Reiterated | 12.10.26on TipRanks 08:55 | −0.7%next day −4.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $168 → $165−1.8% | Buy | +21.6% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $170 → $167−1.8% | Buy | +23.1% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $166 → $163−1.8% | Buy | +20.1% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $161 → $158−1.9% | Buy | +16.4% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $166 → $164−1.2% | Buy | +20.8% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $214 | Buy | +57.7% | Reiterated | 09.10.26on TipRanks 08:15 | +0.2%next day −0.7% · 5 days −2.8% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $210 | Buy | +54.7% | Reiterated | 09.10.26on TipRanks 07:11 | +0.2%next day −0.7% · 5 days −2.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $169 → $168−0.6% | Buy | +23.8% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $171 → $170−0.6% | Buy | +25.3% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $167 → $166−0.6% | Buy | +22.3% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $162 → $161−0.6% | Buy | +18.6% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $167 → $166−0.6% | Buy | +22.3% | Reiterated | 09.10.26on TipRanks Oct 8 23:06 | — | |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $187 | Buy | +37.8% | Reiterated | 08.10.26on TipRanks 21:45 | +0.2%next day −0.7% · 5 days −2.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $168 → $169+0.6% | Buy | +24.5% | Reiterated | 07.10.26on TipRanks Oct 6 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $170 → $171+0.6% | Buy | +26.0% | Reiterated | 07.10.26on TipRanks Oct 6 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $165 → $167+1.2% | Buy | +23.1% | Reiterated | 07.10.26on TipRanks Oct 6 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $160 → $162+1.2% | Buy | +19.4% | Reiterated | 07.10.26on TipRanks Oct 6 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $166 → $167+0.6% | Buy | +23.1% | Reiterated | 07.10.26on TipRanks Oct 6 23:06 | — | |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $207 | Buy | +52.5% | Initiated | 05.10.26on TipRanks Oct 6 05:21 | 0.0%next day +0.4% · 5 days −2.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $165 → $168+1.8% | Buy | +23.8% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $167 → $170+1.8% | Buy | +25.3% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $163 → $165+1.2% | Buy | +21.6% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $158 → $160+1.3% | Buy | +17.9% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $163 → $166+1.8% | Buy | +22.3% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $162 → $165+1.9% | Buy | +21.6% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $164 → $167+1.8% | Buy | +23.1% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $160 → $163+1.9% | Buy | +20.1% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $155 → $158+1.9% | Buy | +16.4% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $160 → $163+1.9% | Buy | +20.1% | Reiterated | 03.10.26on TipRanks Oct 2 23:06 | — | |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $210 | Buy | +54.7% | Reiterated | 01.10.26on TipRanks 07:08 | −1.0%next day +1.0% · 5 days −0.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $162 | Buy | +19.4% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $164 | Buy | +20.8% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $160 | Buy | +17.9% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $155 | Buy | +14.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $161 → $160−0.6% | Buy | +17.9% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| Unknown Analyst | Jefferies | $220 | Buy | +62.1% | Reiterated | 29.09.26on TipRanks Sep 30 23:06 | −1.3%next day +2.7% · 5 days +3.2% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $231 → $214−7.4% | Buy | +57.7% | Reiterated | 28.09.26on TipRanks Sep 29 06:20 | +2.2%next day −1.3% · 5 days +1.5% | ↗ |
| Jeffrey Walch★★★★★★★★★★#5662 · hits 100% · avg +19.5% | Bernstein | $218 | Buy | +60.6% | Reiterated | 25.09.26on TipRanks Sep 26 08:16 | −0.9%next day +2.2% · 5 days +3.7% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $198 → $187−5.6% | Buy | +37.8% | Reiterated | 21.09.26on TipRanks Sep 23 21:45 | −3.1%next day −1.2% · 5 days −1.4% | ↗ |
| Unknown Analyst | CCB Intl. | $188 | Buy | +38.5% | Initiated | 18.09.26on TipRanks Sep 22 23:06 | −3.8%next day −3.1% · 5 days −6.6% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $182 → $183+0.5% | Hold | +34.8% | Assigned | 11.09.26on TipRanks 08:09 | −1.1%next day +1.1% · 5 days −6.3% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $249 → $253+1.6% | Buy | +86.4% | Reiterated | 04.09.26on TipRanks Sep 3 06:35 | −0.7%next day −1.3% · 5 days −0.2% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $195 → $180−7.7% | Buy | +32.6% | Reiterated | 20.08.26on TipRanks 00:07 | — | |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $190 | Hold | +40.0% | Reiterated | 17.08.26on TipRanks Aug 18 07:35 | +1.6%next day +0.5% · 5 days +0.3% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $210 → $215+2.4% | Buy | +58.4% | Reiterated | 17.08.26on TipRanks 09:05 | +1.6%next day +0.5% · 5 days +0.3% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $190 → $165−13.2% | Hold | +21.6% | Assigned | 13.08.26on TipRanks 03:15 | −4.3%next day +1.5% · 5 days +3.4% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $185 → $217+17.3% | Buy | +59.9% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | −0.9%next day +1.6% · 5 days −6.8% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $185 → $194+4.9% | Buy | +43.0% | Reiterated | 03.08.26on TipRanks 08:25 | −1.8%next day −1.9% · 5 days −2.8% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $200 → $210+5.0% | Buy | +54.7% | Reiterated | 03.08.26on TipRanks 07:15 | −1.8%next day −1.9% · 5 days −2.8% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $213 | Buy | +57.0% | Reiterated | 03.08.26on TipRanks Jul 31 08:45 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 31.07.26on TipRanks 12:52 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $215 | Buy | +58.4% | Reiterated | 31.07.26on TipRanks 12:46 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $200 | Buy | +47.4% | Assigned | 31.07.26on TipRanks 11:24 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $230 | Buy | +69.5% | Reiterated | 31.07.26on TipRanks 08:35 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $188 → $215+14.4% | Buy | +58.4% | Reiterated | 31.07.26on TipRanks 07:26 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $186 → $225+21.0% | Buy | +65.8% | Reiterated | 31.07.26on TipRanks 07:26 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $200 → $222+11.0% | Buy | +63.6% | Reiterated | 31.07.26on TipRanks 07:00 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $200 → $204+2.0% | Buy | +50.3% | Assigned | 31.07.26on TipRanks 05:42 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | $200 → $220+10.0% | Buy | +62.1% | Assigned | 31.07.26on TipRanks Jul 30 22:45 | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $210 → $215+2.4% | Buy | +58.4% | Assigned | 30.07.26on TipRanks Jul 31 08:22 | +0.9%next day −10.8% · 5 days −17.5% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $199 → $214+7.5% | Buy | +57.7% | Reiterated | 30.07.26on TipRanks Jul 31 06:52 | +0.9%next day −10.8% · 5 days −17.5% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $213 | Buy | +57.0% | Initiated | 02.06.26on TipRanks Jun 3 04:25 | −4.0%next day +7.3% · 5 days +9.7% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $160 | Buy | +17.9% | Reiterated | 06.04.26on TipRanks Apr 7 08:15 | +0.2%next day −1.2% · 5 days −8.8% | ↗ |
| Uy Ear★★★★★★★★★★#2580 · hits 43% · avg +6.3% | Mizuho Securities | $146 → $175+19.9% | Hold | +29.0% | Reiterated | 12.12.25on TipRanks Dec 11 21:10 | −0.2%next day +1.0% · 5 days −5.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Neurocrine
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $209 at a price of $142 (+47.7%); now: $207 at $136 (+52.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 4 | 1 | 3 | 4 |
| Buy | 24 | 28 | 39 | 31 | 29 | 14 |
| Hold | 8 | 8 | 8 | 9 | 10 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 02.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.93 (from $1.33 to $2.38). Last quarter: $1.39.
Sales
Next quarter’s sales estimate — $1.0B (from $1.0B to $1.1B). Last quarter: $959M.
Best top-analyst consensus in the sector · Healthcare
About Neurocrine
- CEO: Kyle W. Gano
- Employees: 2,500
- 6027 Edgewood Bend Court, San Diego, CA, 92130, US
- www.neurocrine.com
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Data from the stock’s TipRanks forecast page, read 5 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗